#JPM23: This is how we cure can­cer

Cur­ing can­cer, or find­ing new ways to achieve cu­ra­tive progress, ex­tend­ing lives, has be­come a hotbed of ac­tiv­i­ty in bio­phar­ma. End­points Ed­i­tor-in-Chief John Car­roll sat down at JP Mor­gan with a group of in­dus­try ex­perts work­ing on that. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

This is a sub­ject that I’ve been cov­er­ing for­ev­er, and I seem to un­der­stand less and less what’s go­ing on as I go deep­er and deep­er in­to what’s hap­pen­ing. So I’ve brought to­geth­er five great ex­perts in the field to talk about one of the most im­por­tant trends in re­search and de­vel­op­ment to­day, which is where are we go­ing to find the very big trans­for­ma­tion­al ther­a­pies in the near term that are go­ing to make some sig­nif­i­cant dif­fer­ences to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER